Parkinson's treatment could go monthly: new injection tested

NCT ID NCT06798519

Ongoing Disease control Sponsor: Guangzhou Henovcom Bioscience Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests a new long-acting injection called HNC364, which turns into the Parkinson's drug rasagiline in the body. Researchers want to see how much of the drug gets into the bloodstream compared to taking rasagiline pills daily. The study involves 30 healthy adults who receive either the injection every 4 weeks or the oral tablet. Safety and side effects are also closely monitored.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HNC364 (a long-acting injectable form of rasagiline)
What this could lead to: If successful, this could lead to a once-monthly injection for Parkinson's disease, potentially improving medication adherence compared to daily pills.
What could go wrong: This is a very early Phase 1 study in only 30 healthy adults, not people with Parkinson's. It primarily measures drug levels and safety, not whether it improves symptoms. The injection may cause side effects like injection site reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE (PD)

Contacts and locations

Locations

Frontage Clinical Services, Inc.

Secaucus, New Jersey, 07094, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.